Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
- Indications Hepatitis C
- Focus Therapeutic Use
- 28 Jun 2017 Status changed from active, no longer recruiting to completed.
- 19 Jul 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2017.
- 19 Jul 2016 Status changed from not yet recruiting to active, no longer recruiting.